Registered title, quoted from ClinicalTrials.gov
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
An open trial on stomach cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05934331, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
Participants with advanced gastrointestinal tumors diagnosed histologically and/or cytologically and who have failed or are intolerant to prior standard first-line therapy (imaging confirmation required)
Inclusion criterion 5
Previous immunotherapy and grade ≥3 irAE or grade ≥2 immune-related myocarditis. (for cohorts treated with combination PD-1).
Exclusion criterion 4
Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
Exclusion criterion 5
Participants have received Strong inhibitor/strong inducer of CYP3A4 within 14 days prior to first dose.
Exclusion criterion 12
Participants who received major surgery or interventional treatment within28 days prior to the first dosing of IMP.
Exclusion criterion 18
Eastern Cooperative Oncology Group (ECOG) performance status of0-1.
Inclusion criterion 3
Participants with known HER2-positive gastric cancer/adenocarcinoma of the gastroesophageal junction
Exclusion criterion 1
Participants with HIV infection, active HBV or HCV infection.
Exclusion criterion 25
Child-bearing potential female who have positive results in pregnancy test within 7 days before the first dose or are lactating.
Exclusion criterion 26
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05934331, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Participants who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
- Aged 18-80 years old (including boundary values) .
- Eastern Cooperative Oncology Group (ECOG) performance status of0-1.
- Life expectancy ≥ 3 months.
- Participants with advanced gastrointestinal tumors diagnosed histologically and/or cytologically and who have failed or are intolerant to prior standard first-line therapy (imaging confirmation required)
- CLDN18.2-positive subjects.
- At least one measurable lesion.
- Participants must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose.
- Participants who are able to communicate well with investigators and understand and adhere to the requirements of this study.
Exclusion Criteria:
- Participants with known HER2-positive gastric cancer/adenocarcinoma of the gastroesophageal junction
- Participants have participated in any other clinical trial within 28 days prior to 1st dosing of investigational medicinal product (IMP).
- Participants with anti-tumor treatment within 21 days prior to 1st dosing of IMP.
- Previous immunotherapy and grade ≥3 irAE or grade ≥2 immune-related myocarditis. (for cohorts treated with combination PD-1).
- Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
- Present peripheral sensory or motor neuropathy ≥ grade 2.
- Participants with uncontrolled pain.
- Participants with symptomatic/active central nervous system(CNS)metastases.
- Participants who have uncontrollable third space effusion.
- Participants with known hypersensitivity to antibody therapy.
- Participants have treated with the same target.
- Participants have received Strong inhibitor/strong inducer of CYP3A4 within 14 days prior to first dose.
- Use of any live vaccines within 28 days prior to 1st dosing of IMP.
- Participants with current or previous interstitial lung diseases or pneumonia requiring oral or intravenous glucocorticoids for adjuvant therapy.
- Participants on anticoagulants, such as heparin and vitamin K antagonists.
- Clinically uncontrollable persistent recurrent vomiting.
- Uncontrollable/severe gastrointestinal bleeding, ulceration or diarrhea within 28 days prior to first dose of IMP.
- Participants who received major surgery or interventional treatment within28 days prior to the first dosing of IMP.
- Participants who have other cancers, other than the one treated in this trial, within 2 years prior to screening.
- Participants who have severe cardiovascular disease.
- Participants who have uncontrolled or severe illness.
- Participants who take systemic corticosteroids (> 10 mg daily prednisone equivalents) or other systemic immunosuppressive medications within 2 weeks prior to the first dosing of IMP.
- Participants with a known history of autoimmune diseases.
- Participants who have a history of immunodeficiency disease.
- Participants with HIV infection, active HBV or HCV infection.
- Child-bearing potential female who have positive results in pregnancy test within 7 days before the first dose or are lactating.
- Participants who have a known psychiatric diseases or disorders that may affect compliance with the trial.
- Participants who is judged as not eligible to participate in this study by the investigator.
Quoted from ClinicalTrials.gov, NCT05934331, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05934331, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.